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Abstract
Irritable bowel syndrome (IBS) is a gut- brain disorder in which symptoms are shaped 
by serotonin acting centrally and peripherally. The serotonin transporter gene SLC6A4 
has been implicated in IBS pathophysiology, but the underlying genetic mechanisms 
remain unclear. We sequenced the alternative P2 promoter driving intestinal SLC6A4 
expression and identified single nucleotide polymorphisms (SNPs) that were associ-
ated with IBS in a discovery sample. Identified SNPs built different haplotypes, and 
the tagging SNP rs2020938 seems to associate with constipation- predominant IBS 
(IBS- C) in females. rs2020938 validation was performed in 1978 additional IBS pa-
tients and 6,038 controls from eight countries. Meta- analysis on data from 2,175 IBS 
patients and 6,128 controls confirmed the association with female IBS- C. Expression 
analyses revealed that the P2 promoter drives SLC6A4 expression primarily in the 
small intestine. Gene reporter assays showed a functional impact of SNPs in the P2 
region. In silico analysis of the polymorphic promoter indicated differential expres-
sion regulation. Further follow- up revealed that the major allele of the tagging SNP 
rs2020938 correlates with differential SLC6A4 expression in the jejunum and with 
stool consistency, indicating functional relevance. Our data consolidate rs2020938 as 
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1  | INTRODUC TION
Accumulating evidence has shown that irritable bowel syndrome 
(IBS) is not just a functional gastrointestinal (GI) disorder, but rather 
represents a prototypical gut- brain disorder.1,2 IBS patients pres-
ent with abdominal pain and variable alterations in bowel habits, 
which define the subtype of IBS. These subtypes are diarrhoea- 
predominant IBS (IBS- D), constipation- predominant IBS (IBS- C), 
mixed IBS (IBS- M) or unspecified IBS (IBS- U).2,3 IBS is one of the 
common GI disorders, and depending on the applied diagnostic 
Rome criteria, it has a prevalence of 10.1% (Rome III) and 4.1% (Rome 
IV) worldwide,4 and 70%- 75% of affected individuals are female.2,5
Bidirectional communication between the gut and the brain via 
the gut- brain axis is influenced by the immune system, hormones 
and neurotransmitters.2,3 Serotonin, or 5- hydroxytryptamine (5- 
HT), acts as a neurotransmitter, paracrine factor, endocrine hor-
mone and growth factor to connect the gut and the brain.6 Enteric 
5- HT regulates a range of gut functions, including GI motility, se-
cretion and visceral sensation.6 Of note, alterations in both central 
and peripheral 5- HT contribute to visceral hypersensitivity in IBS.7 
Furthermore, 5- HT influences behaviour and modulates the immune 
and nervous systems. It affects the vagus nerve and is involved in 
the GI symptoms and comorbid disorders associated with IBS.6,8,9 In 
line with its important gut- related functions, serotonin is predom-
inantly produced in the gut and is influenced by gut microbiota.10
IBS is caused by extrinsic factors such as stress, infection and diet, 
as well as intrinsic factors including the individual genetic background 
and microbiota.7,11 One of the most extensively analysed genes in 
IBS is SLC6A4 (NM_001045), which encodes the serotonin re- uptake 
transporter (SERT).11 This transporter is responsible for the re- uptake 
of serotonin from the synaptic cleft into the presynaptic neuron and 
from the interstitial space into the gut epithelium and enterocytes.
The expression of different 5’ SLC6A4 isoforms is driven by two 
distinct promoters— P1 and P2 12- 14 (Figure 1). P1 controls the ex-
pression of isoforms 1a and 1b, which have non- coding exons repre-
senting alternatively used 5’ untranslated regions (5’UTRs) upstream 
of exon 2. A novel SLC6A4 isoform is generated when exon 1c and 
1b are spliced to exon 2, and expression of this isoform is driven by 
the P2 promoter downstream of P1 (Figure 1). This novel isoform is 
predominantly expressed in the GI tract.14
A 44- bp insertion/deletion polymorphism, 5- HTTLPR (short, 
long: s/l), in the P1 promoter of SLC6A4 had been associated with 
IBS, although some studies have failed to confirm this association (for 
a summary, see11 ). The s allele of promoter P1 is a less potent driver 
of mRNA expression, so may diminish serotonin re- uptake, leading to 
higher 5- HT levels and increased bioavailability in the gut.12,15 5- HT 
levels were higher in rectal biopsies of IBS- D patients compared with 
biopsies from healthy individuals or individuals with IBS- A or IBS- 
C.16 These 5- HT levels were significantly higher in carriers of the s/s 
genotype than in carriers of the s/l or l/l genotype.16 Increased 5- HT 
levels and the s/s genotype correlated significantly with IBS- D and 
abdominal pain,16 whereas the l/l genotype was associated with IBS- 
C. The s/l genotype correlated with SERT protein expression (SERT 
expression was lower in colon biopsies of s allele carriers).15,16
The P1 s/l polymorphism is also associated with behavioural traits 
and psychiatric conditions like anxiety and depression that are often 
comorbid with IBS, supporting the biopsychosocial model of IBS.13,17,18 
Furthermore, stress is involved in shaping the phenotype.19,20 These 
findings suggest that the P1 s/l polymorphism might alter central neu-
robiological functions in the brain to induce behavioural phenotypes.
Disturbed GI function is well documented in IBS, but the underly-
ing neuromolecular mechanisms are not well understood. Serotonin 
metabolism is altered in IBS, and normalizing serotonin levels can 
ameliorate IBS symptoms.2,21 Studies have revealed variable results 
regarding levels of 5- HT and its metabolites in IBS,15,22- 25 but SERT 
expression was consistently found reduced in GI tissues of IBS pa-
tients, which supports findings of increased 5- HT in the tissue or 
blood.22,23 How genetic factors affect 5- HT in IBS is still poorly 
understood. Unravelling these genetic mechanisms may help to de-
velop effective, individualized treatment strategies for IBS.
In this study, we aimed to elucidate the impact of the alternative 
P2 promoter of SLC6A4 in IBS pathogenesis. We sequenced the P2 
region of SLC6A4 in a discovery sample from the United Kingdom 
and identified SNPs that were associated with IBS- C in females. To 
validate the initial association of the SNPs with IBS- C, we genotyped 
a tagging SNP in eleven cohorts from eight additional countries. 
Meta- analysis confirmed the initial finding. Follow- up analyses of 
associated variants were performed by luciferase reporter assays 
to assess their functional impact. Expression analysis in different GI 
regions uncovered the relevance of the P1- and P2- driven isoforms 
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of SLC6A4 in IBS pathogenesis.
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in the gut. We also analysed the functional impact on promoter reg-
ulation in silico. The genotype- phenotype correlations revealed the 
functional consequences of the identified SNPs.
2  | MATERIAL AND METHODS
The experimental design is summarized in Figure S1. Variants 
were detected using biospecimens from human subjects, and in 
vitro and in silico analyses determined the functional relevance of 
these detected variants. Additional information can be found in the 
Supplementary Data.
2.1 | IBS patients and controls
SNP analysis was carried out on IBS patient and control DNA from 
IBS expert centres, comprising twelve cohorts from eight coun-
tries including Chile, Germany, Greece, Ireland, Spain, Sweden, the 
United Kingdom and the United States (Table S1). Comparative 
SLC6A4 expression analyses were performed on small and 
large intestine biopsies from three case- control cohorts from 
Spain (Barcelona) and Germany (Berlin and Erlangen- Nürnberg) 
(Table S2).
All participants were Caucasian. Written informed consent was 
obtained from all subjects, and experiments were performed in ac-
cordance with the principles of the WMA Declaration of Helsinki 
and the Department of Health and Human Services Belmont 
Report. All studies were approved by the following local ethics 
committees: Germany, Heidelberg: Ethical Committee, Medical 
Faculty of the Heidelberg University Hospital (S067/2010); 
Germany, Berlin: Ethical Committee Charité Berlin Campus Mitte 
(No Si 285); Germany, Erlangen, Ethical Committee, Medical 
Faculty of the University of Erlangen- Nürnberg (Ethik No. 4581); 
Chile, Santiago: Ethical Committee Hospital Clínico Universidad 
de Chile (Acta- No 25/2015, No 27/2019); Greece, Athens: Ethical 
committee of the Aretaieio University Hospital, Medical School, 
National and Kapodistrian University of Athens (008/21- 11- 2017); 
Ireland, Cork: Clinical Research Ethics Committee (APC024); 
Spain, Barcelona: Ethics Committee of Hospital Universitari 
Vall d´Hebron (PR(AG)159/2011) and Ethics Committee of Par 
de Salut Mar (2005/2106/I); Sweden, Stockholm: Karolinska 
Institutet's Ethics Review Board (dnr 2009/1059- 31/3); Sweden, 
Gothenburg: Regional Ethical Review Board in Gothenburg (S489- 
02 and 731- 09); United Kingdom, Manchester: NHS National 
Research Ethics Service, South Manchester Research Ethics 
Committee, Genetics of Functional GI Disorders (09/H1003/1); 
United Kingdom, Nottingham: clinical trial clinicaltrials.gov (iden-
tifier NCT00745004), approved by Nottingham Research Ethics 
Committee 2 (REC reference number 08/H0408/134)26; USA, St. 
Louis, WA: Washington University in St. Louis, Human Research 
Protection Office (IRB ID #: 201 103 220); USA, Los Angeles, CA: 
University of California Los Angeles, HORPP Office of the human 
research protection programme (IRB#12- 001802- CR- 00004). 
Furthermore, a cohort of IBS patients and controls from the 
United Kingdom, United States and Canada were included in 
this study; these were kindly provided by Glaxo Smith Kline (UK, 
GenIBS/2005/0000/01).
2.2 | Preparation of genomic DNA
Genomic DNA was prepared from blood or saliva samples taken 
from patients and healthy controls as described previously.27,28
2.3 | Genotyping of the tag SNP rs2020938
Unless otherwise stated in the Supplementary Methods section, 
SNP genotyping of the tagSNP rs2020938 in patients and controls 
from the IBS expert centres was carried out using the KASPar® 
assay (KBiosciences, Ltd., Hoddesdon, United Kingdom) according 
to the manufacturer's instructions (for primer sequences, Table S4). 
Thermal cycling was performed in a Mastercycler vapo.protect ther-
mal cycler (Eppendorf). An initial 15 minutes incubation at 95℃ was 
followed by 20 cycles consisting of 10 seconds at 94℃, 5 seconds 
at 57℃, and 10 seconds at 72℃, followed by 23 cycles consisting 
of 10 s at 94℃, 5 seconds at 57℃, and 10 seconds at 72℃. After 
thermal cycling, results were analysed using the fluorescence plate 
reader of the 7500 Fast Real- Time PCR System (Applied Biosystems). 
Genotyping was repeated in 10% of the samples as a quality control 
measure, and the same results were obtained.
2.4 | Statistical analysis
2.4.1 | Statistical analysis of the genotyping data
Genotype frequencies, association analyses and tests for deviation 
from the Hardy- Weinberg Equilibrium (HWE) were compared as 
described previously.27 Genotype relative risks of IBS and IBS sub-
types were quantified by odds ratios (ORs) with the corresponding 
95% confidence intervals (CIs) based on a logistic regression model 
under a dominant inheritance model (TT compared with TC and CC 
genotypes).29
2.4.2 | Statistical analysis for genotype- phenotype 
associations in German IBS- Net samples
Groups were compared (genotype status of SLC6A4 SNPs) according 
to the following clinical phenotype features: IBS subtype (using the 
ROME III criteria); stool consistency (using the Bristol stool scale [BSS]) 
and stool frequency and IBS symptom severity (using the IBS symptom 
severity scale) in 134 female IBS patients from German IBS- Net sam-
ples. Chi- square tests were used to analyse differences in frequencies 
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of IBS subtype (IBS- C, IBS- D, IBS- M and IBS- U) and stool consistency 
(hard, soft, normal). Additionally, non- parametric Kruskal- Wallis tests 
were conducted to analyse potential differences in stool frequency 
and IBS symptom severity. P- values <.05 were considered statistically 
significant; a P- value <.10 was considered a trend. Analyses were car-
ried out using IBM SPSS Statistics for Windows, version 25.
2.5 | Meta- analysis
Results from single studies were combined using fixed and random ef-
fects meta- analyses. Results were represented by Forest plots as fol-
lows: CIs on the OR for each study were indicated by horizontal lines, 
study- specific ORs by squares proportional to the study size and com-
bined summary estimates by a diamond with horizontal limits indicat-
ing the confidence limits. Data were analysed using the rmeta package 
from the free Software Environment for Statistical Computing R.
3  | RESULTS
3.1 | Seven common variants identified in the 
SLC6A4 P2 promoter in a discovery cohort from the 
United Kingdom
The alternative promoter P2 of SLC6A4 primarily drives expression 
of the serotonin transporter in the GI tract.14 To see whether ge-
netic variants within this alternative promoter might regulate ex-
pression and thus contribute to or protect from IBS, we performed 
Sanger sequencing of this genomic region in a discovery cohort from 
the United Kingdom consisting of 197 IBS patients (98 IBS- D, 99 
IBS- C) and 90 healthy control individuals. In this initial analysis, a 
1,319- bp spanning region of the P2 promoter and the downstream 
5'UTR including exons 1c and 1b were screened for genetic variants 
(Figure 1).
Sequence data were compared with the SLC6A4 reference 
sequence NC_000017 (http://www.ncbi.nlm.nih.gov/nucco 
re/22458 9808) to assess genetic variability in the P2 promoter. 
Twelve sequence variants were identified, seven of which were 
common SNPs with a minor allele frequency (MAF) above 0.05 
(Table S8).
3.2 | Identified variants are associated with IBS- C 
in the discovery cohort of female patients
Association analysis, assuming a dominant model, revealed IBS- C to 
be nominally associated with five of the seven common SNPs tested 
(Table 1).
Further analysis applying the dominant model revealed a nominal 
association between IBS- C and the five associated SNPs in female 
patients. However, due to the small sample size for males an associ-
ation cannot be excluded (Table 2).
No deviation from HWE was detected in any groups other than 
IBS- C and female IBS- C (Table S9).
3.3 | Haplotype block analysis identified a tag SNP 
for follow- up analyses in female IBS- C patients
Haplotype analysis of the seven common SNPs in female IBS- C 
patients and female controls was performed using Haploview v4.2 
(https://www.broad insti tute.org/haplo view/haplo view). All SNPs 
displayed a high linkage disequilibrium (LD), defining one haplo-
type block with three common haplotypes (Figure 2A). The SNP 
rs2020938 was selected as a representative tag SNP for subsequent 
F I G U R E  1   Schematic showing the upstream region of SLC6A4 including the promoter regions P1 and P2. Oval shapes represent exons, 
and connecting lines indicate introns. Upstream regions of the start ATG (5’untranslated region [5’UTR]) are indicated by a light yellow line. 
Alternative upstream non- coding exons are indicated in light blue/green and downstream coding exons are labelled in dark green. Exons 1a, 
1b, 1c and 2, promoter 1 (P1) and the alternative promoter 2 (P2) are indicated (adapted from14). Not drawn to scale
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analyses because it showed the strongest association with IBS- C in 
female patients (P = .007; OR, 0.39; CI, 0.2- 0.78). To determine the 
functional relevance of these SNPs, we further analysed the two 
most contrary blocks, AATTTC and CCCCTCG, hereafter termed 
major and minor, respectively.
3.4 | Functional readout of SNPs in luciferase 
reporter assays
To investigate the functional relevance of the SNPs arranged in the 
two haplotype blocks, representative genomic regions were ampli-
fied from the genome of respective carriers, cloned upstream of a 
luciferase reporter cassette and sequence verified (Figure 2B). The 
major and minor haplotype reporter constructs were analysed in 
four human cell lines: HEK293T embryonic kidney cells, SH- SY5Y 
neuroblastoma cells, as well as Caco 2 and Colo 320, both colon car-
cinoma cells (Figure 2C). All cell lines endogenously express SLC6A4 
as shown by RT- PCR (see Figure S2). Luciferase reporter assays re-
vealed that the minor haplotype in the P2 promoter region carrying 
the rs2020938 variant drives less gene expression than the major 
haplotype does in all four cell lines (Figure 2C).
3.5 | Replication analysis of rs2020938 in twelve 
additional cohorts from eight countries confirmed the 
association with IBS- C in female patients
To validate the association between rs2020938 and IBS- C in female 
patients from the UK discovery sample, we genotyped rs2020938 
in 1978 additional IBS patients and 6,038 controls from twelve co-
horts in eight countries: two from the United Kingdom, two from 
Germany, three from the United States and one each from Ireland, 
Sweden, Spain, Greece and Chile (Table S3). Cohorts with 30 or 
fewer individuals in subgroup analyses were not included in the 
meta- analysis. The average number of IBS patients per study was 
167 (range, 34- 455).
Meta- analysis of genotype data from 2,175 IBS patients and 
6,128 controls confirmed the association between rs2020938 and 
IBS- C in female patients (OR = 0.75 and 0.78, P = .0458 and .05 
using a fixed and random effects model) (Figure 3A). Analyses in-
volving male patients or non- IBS- C subtypes did not show a statisti-
cally significant association (data not shown).
In all control individuals and most IBS patients, no deviations 
from HWE expectations were detected except for IBS- C and female 
IBS- C patients from the United Kingdom (P = .027- 0.041) and IBS 
overall, IBS- C and female IBS- C patients from Greece (P = 1.65 × 10- 
12- 1.68 × 10- 12) (Table S9).
3.6 | Comparative expression analysis of SLC6A4 in 
different GI regions
Analysis of expression driven by the P1 and P2 promoter in different 
intestinal regions confirmed that the P2 promoter primarily drives 
SLC6A4 expression within the small intestine. In particular, robust 
expression was detected in the jejunum (Ct: 27- 31) and even more 
pronounced in the ileum (Ct: 22- 27). In contrast, within the large in-
testine Ct values were much higher, within colon (Ct: 30- 37) and the 
TA B L E  1   SNP association data of IBS- C patients from the 








rs12150214 0.41 0.21;0.8 .008
rs2020936 0.39 0.2;0.77 .006
rs2020937 0.91 0.47;1.76 .788
rs2029038 0.44 0.23;0.85 .014
rs2020939 1.34 0.7;2.54 .373
rs25528 0.44 0.23;0.87 .017
rs6354 0.46 0.24;0.9 .023
Note: P- values for the dominant model (TT compared with TC and CC 
genotypes). P- values <.001 were rated significant after Bonferroni 
correction. P- values smaller than 0.05 were considered ‘nominal 
associations’ a priori. OR, odds ratio; CI, confidence interval.
TA B L E  2   SNP association data of common SNPs (MAF > 0.05) 
separated by sex in IBS- C patients from the discovery cohort 









rs12150214 0.41 0.20;0.83 .012
rs2020936 0.39 0.19;0.78 .008
rs2020937 1.14 0.57;2.27 .715
rs2029038 0.39 0.20;0.78 .007
rs2020939 1.14 0.58;2.24 .705
rs25528 0.44 0.22;0.89 .021
rs6354 0.47 0.23;0.95 .036
Males
rs12150214 0.42 0.04;4.18 .428
rs2020936 0.42 0.04;4.18 .428
rs2020937 0.15 0.01;1.50 .071
rs2029038 1.27 0.18;8.79 .808
rs2020939 NA 0.00;NA .1528
rs25528 0.48 0.05;4.81 .508
rs6354 0.37 0.04;3.65 .357
Note: P- values of the dominant model. P < .001 was rated significant 
after Bonferroni correction. P < .05 was rated nominally a priori. OR, 
odds ratio; CI, confidence interval.
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sigma (Ct 31- 37) and thus, the P2- driven isoform not found to be 
consistently expressed. Of note, the P1 promoter- driven transcript 
was neither detectable at a robust level in the small nor in the large 
intestine (Table S10). This is in line with expression data of different 
tissues from the GTEx portal (Release v08, https://gtexp ortal.org/
home/), which shows highest expression in the lung, followed by the 
small intestine (terminal ileum, data from n = 187 donors, median 
TPM (transcripts per million) = 4.219). Expression in other tissues was 
much lower (eg oesophagus, n = 555 donors, median TPM = 1.645, 
all others: median TPM below 0.2). In addition, isoform- specific ex-
pression analysis confirmed that the P2- driven isoform is the most 
abundantly expressed isoform in the small intestine (Figure 4).
Further follow- up studies in tissue samples of IBS patients and 
controls revealed that the homozygous genotype TT of the major 
allele of rs2020938 correlated with significantly altered expression 
in the jejunum (P = .0398), corroborating a functional impact of the 
SNP on SERT expression (Figure 3B). In contrast, overall expres-
sion was not different between IBS patients and control individuals 
(Figure 3C). Moreover, ileum samples from a German centre showed 
no correlation with the rs2020938 genotype, potentially because of 
the small number of variant carriers (data not shown).
3.7 | Genotype- phenotype correlation
Correlation analysis of nCounter expression data of jejunum sam-
ples was performed separately in IBS patients of TT or TC genotype 
carriers from the Spanish centre. This revealed a significant correla-
tion between SLC6A4 expression and stool consistency (assessed by 
the BSS) in TC cases only (r = .75; P = .02) (Figure 3D). Hence, lower 
SLC6A4 expression in TC carriers is associated with softer stools.
These findings were corroborated by genotype- phenotype as-
sociation data (IBS subtype, stool consistency, stool frequency and 
IBS symptom severity) of 134 female IBS patients from the IBS- 
Net in Germany. No associations were found for IBS subtype, stool 
frequency or symptom severity. However, SLC6A4 TC/CC carriers 
showed a trend for softer stools (according to the BSS) compared 
with TT carriers (P = .053).
3.8 | Impact of DNA variants on transcription factor 
binding capacity
We performed comparative transcription factor binding site analysis 
in the major and the minor (protective) haplotype genomic regions 
where the tag SNP rs2020938 resides. We used the ePOSSUM2 
online tool (https://www.mutat iondi still er.org/ePOSS UM2/) to 
predict the impact of DNA variants on transcription factor bind-
ing. This revealed 52 novel binding sites in the variant sequence, 
32 of which were predicted by more than three models (Table S11). 
Ingenuity pathway analysis assembled these genes into three major 
networks according to the top diseases and functions as follows: 1. 
gene expression, cell cycle and cellular development; 2. gene ex-
pression, cell morphology and humoral immune response; and 3. 
F I G U R E  2   A, Genomic structure and linkage disequilibrium (LD) of the SNP markers in the SLC6A4 P2 promoter region in female patients 
with IBS- C. Strong LD is indicated by bright red (LOD ≥2, D' = 1), and no LD is indicated by white (LOD < 2, D' < 1). Pink (LOD = 2, D' < 1) 
and blue (LOD < 2, D' = 1) indicate intermediate LD. Association analyses of block 1 for IBS patients versus controls revealed five significant 
P- values. All SNPs with a MAF > 5% were included. The analysed genomic region is shown as a white bar above. The relative positions of 
SNPs within this region are represented by vertical lines. The graphics underneath show the degree of LD among the SNPs. Red boxes 
without numbering represent a LD value of 100 (source: Haploview; Copyright (c) 2003- 2006 Broad Institute of MIT and Harvard). The 
tag SNP rs2020938 was selected for subsequent replication analysis. B, Schematic of the cloned upstream region of SLC6A4 including the 
promoter regions P1 and P2, which harbour the major and minor haplotypes. The scheme is not drawn to scale. Boxes indicate exons, and 
lines indicate introns. ATG indicates the start codon. The upstream region of the ATG is indicated in light green, the downstream region 
in grey. Exons 1a, 1c, 1b, and 2 and the P1 and P2 promoters are illustrated. C, Data of the gene reporter luciferase assay. The promoter 
activities of the alternative SLC6A4 promoter P2, composed of the major or the minor haplotype and harbouring the tag SNP rs2020938, 
were analysed in HEK293T, Colo 320, Caco 2 and SH- SY5Y cells. Relative luciferase activities are indicated (mean ± SE). Firefly luciferase 
values were normalized relative to renilla luciferase values; the number of performed experiments (n = 9- 15; * P < .05, ** P < .01, *** 
P < .001, **** P < .0001) was corrected for multiple testing using the Benjamini, Krieger and Yekutieli procedure
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gene expression, auditory disease and inflammatory disease. Nine 
factors assembled in the overlay network have been implicated in 
GI disorders (Figure 5A, highlighted in orange). Data reported in the 
GTEx portal (release v08, https://gtexp ortal.org/home/) confirmed 
that most of these genes are moderately to highly expressed in GI 
tissues (Figure 5B). Subsequent analysis of ChIP Atlas data (https://
chip- atlas.org/search) to collect further evidence and validate ePOS-
SUM data revealed all predicted transcription factors but nine to be 
included. Interestingly, eight of the predicted transcription factors 
were found to indeed co- precipitate and thus interact with SLC6A4: 
Among those, ETS1, FOXP1, MITF, RAD21 and ZBTB7A are also in-
cluded in the interaction network (Figure 5, Table S11).
4  | DISCUSSION
We have discovered a novel, functionally relevant cis- regulatory 
promoter haplotype in the SLC6A4 gene that is associated with 
IBS- C in females. This further supports the physiological relevance 
of SERT in IBS pathogenesis and consolidates the importance of 
the serotonergic pathway in regulating gut homeostasis and IBS 
development.
It remains unclear whether the deletion/insertion polymorphism 
s/l in the P1 promoter region of the SLC6A4 gene plays a role in IBS 
development.11 This prompted us to investigate the alternative pro-
moter, P2. The s/l polymorphism has been associated with increased 
susceptibility to stress- provoked psychopathologies20,30 that are 
comorbid with IBS. We wondered whether the gut- predominant iso-
form might help to dissect the role of SERT in the GI tract.
A recent comprehensive meta- analysis based on more than 7000 
individuals, including more than 3400 IBS and 3600 control cases, 
reported that the SLC6A4 s/l polymorphism correlated with the risk 
of IBS- C in Asians and Caucasians.31 Here, we show that the SLC6A4 
P2 promoter drives expression in the gut mucosa and, predomi-
nantly, in the small intestine. Our finding that the P2- driven isoform 
is predominantly expressed in the small intestine is supported by 
data in the GTEx portal (https://gtexp ortal.org/home/). Of note, the 
predominant expression of SERT within the small intestine is also 
in line with previous studies.32,33 The lack of robust expression of 
the SLC6A4 P1- driven isoform in the small and large intestine chal-
lenges the role of the P1 s/l polymorphism in the gut. Furthermore, 
how the P1 promoter- driven isoform could shape a GI phenotype is 
unknown. The reported association of the P1 promoter s/l polymor-
phism with IBS- C may be attributed to comorbid conditions, such 
F I G U R E  3   A, Forest plots illustrating genotype risks of rs2020938 of IBS- C in females. Genotype risk is shown as odds ratios (OR) 
with corresponding 95% confidence intervals (CIs) and is based on a logistic regression model under dominant genetic penetrance. CIs for 
each study are indicated by horizontal lines, ORs by squares that reflect study sizes, and summary estimates by diamonds with horizontal 
limits at confidence limits and with a width inversely proportional to the standard error. Only data sets with more than 30 individuals per 
genotype group were included. The I2 of 24% and τ2 of 0.03 suggest relatively low heterogeneity between cohorts. Both fixed effects and 
random effects models result in similar effect estimates (fixed effect model: OR, 0.782; CI, 0.614- 0.995; random effects model: OR, 0.747; 
CI, 0.559- 1.000; P- values = .0458 and .05, respectively). B- D, Expression data of the SLC6A4 P2- driven isoform from tissue samples from 
the jejunum: B, qPCR results showing jejunal mucosal expression of SLC6A4 P2 isoform and genotype correlation of the tag SNP rs2020938 
representative for the polymorphic P2 region. C, Comparative expression analysis of IBS and healthy controls by qPCR. D, Correlation 
analysis of nCounter expression data in TC carriers of rs2020938
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as behavioural phenotypes. This is supported by the fact that 80% 
of IBS patients present with some form of psychological comorbid-
ity.2 However, the authors of the meta- analysis did not stratify for 
comorbid phenotypes like anxiety and depression, so this remains 
elusive at present.
How factors such as stress and trauma influence gene- 
environment and gene- gene interactions has also not been addressed 
to date.31 Sex differences were recently described in the modulation 
of serotonin in the thalamus, and 5- HT- binding studies showed that 
5- HTTP may affect males and females differently. Furthermore, se-
rotonergic signalling is affected differently in males and females with 
affective disorders, suggesting that sex- dependent availability of se-
rotonin transporters in the thalamus contributes to the risk of affec-
tive disorders.24,34,35 Recent reports of an association between rare 
SLC6A4 variants and psychiatric comorbidity in IBS are very much in 
line with the biopsychological model of IBS.36
Variants in the SLC6A4 promoter can affect the response to 
treatment. For example, IBS- D patients with the P1 l/l genotype 
respond better to the 5- HT3 receptor antagonist alosetron,
37,37 
whereas IBS- C patients with the P1 polymorphism l/l respond 
poorly to the 5- HT4 receptor agonist tegaserod compared with s/l 
or s/s carriers.38 Therefore, our finding that the SNP rs2020938 is 
associated with IBS- C in females may be relevant to novel pharma-
cogenetic treatments.
In vitro luciferase assays supported our initial hypothesis that 
the protective SNP rs2020938 in P2 reduces expression of the 
GI- predominant SERT isoform. Follow- up analysis of tissue sam-
ples from IBS patients and controls showed that carriers of the 
F I G U R E  4   Exon- exon junction expression data from different tissues modified from the GTEx portal (v8). The P1- driven isoforms are 
represented by junction 15 and 16, whereas the P2- driven isoform is represented by junction 14 (marked in red), which shows a highly 
prominent expression compared with 15 and 16 in the small intestine (terminal ileum, data from n = 187 donors included, median TPM 
4.219). All other tissues, except the lung, show much lower expression levels (eg oesophagus n = 555 donors, median TPM 1.645, all others: 
median TPM below 0.2). TPM, transcripts per million (adapted from Junction Expression of SLC6A4: ENSG00000108576.9 solute carrier 
family 6 member 4 [Source: HGNC Symbol; Acc:HGNC:11050] GTEx portal: https://gtexp ortal.org/home/)
10  |     MOHR et al.
rs2020938 minor allele seem to have higher SERT expression in 
the jejunum; this may confirm a functional impact of this SNP on 
SERT expression. Further genotype- phenotype correlations in gut 
tissue of IBS patients seem to corroborate our findings— carriers of 
the protective C allele with lower expression of the serotonin trans-
porter P2 promoter- driven isoform had softer stools. This is in line 
with the trend for an association between TC/CC carrier status and 
softer stools observed within the German IBS- Net replication co-
hort. Our genotype- phenotype correlations also agree with earlier 
studies showing that 5- HT levels correlate negatively with SERT 
expression15,22,23 in IBS- D, which is characterized by softer stools. 
Decreased levels of 5- HT have also been reported in IBS- C22- 24 and 
might be caused by increased SERT expression. This intriguing find-
ing shows, for the first time, that bowel habits correlate with the car-
rier status of polymorphisms within the SLC6A4 P2 promoter, which 
drives expression in the GI tract.
The potential functional impact of rs2020938 is emphasized 
by recent data in the OMNI database (https://omni.telen tilab.com/
searc h=rs202 0938/page=1) indicating that rs2020938 presumably 
acts as a modifier. Moreover, single- tissue eQTLs analysis within the 
GTEx portal showed significant eQTL signatures for rs2020938 in 
brain regions such as the amygdala and the cerebellum for a tran-
script termed AC006050.2 and for SUZ12P (SUZ12 polycomb re-
pressive complex 2 subunit pseudogene) and SSH2 (slingshot protein 
phosphatase 2) in the tibial nerve, but in no other nerve or gut tissue. 
(Table S12). AC006050.2 and for SUZ12P have no annotated func-
tion. AC006050.2 seems to be a non- coding RNA, and SUZ12P is a 
pseudogene. SSH2 belongs to the SSH phosphatase gene family com-
posed of three members (SSH1, SSH2 and SSH3) known to control 
essential cellular functions, including invasion, migration and motil-
ity. SSH2 was recently reported to drive proliferation in colon cancer 
stem cells.39 How these eQTL findings might relate to IBS remains 
unclear.
The polymorphic P2 promoter region harbours more than 50 
novel transcription factor binding sites. These transcription factors 
have been annotated to three major networks, including gene ex-
pression and cellular development, morphology and function, and 
humoral immune response and inflammatory disease. Furthermore, 
F I G U R E  5   A, Network analysis B, GTEx expression data of the 52 transcription factors (highlighted in yellow) predicted to bind 
differently within the polymorphic P2 promoter region. The factors coloured in orange have previously been implicated in GI disorders
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the GTEx database shows that most of these transcription factors 
are robustly expressed in GI tissues, indicating a possible relevance 
to the pathogenesis of IBS. Interestingly, nine have been implicated 
in GI disorders; for example, Nfil3 deficiency has been associated 
with colitis, NFIL3 is a susceptibility gene for inflammatory bowel dis-
ease,40,41 and TCF7L2 has been implicated in colorectal cancer.42,43
GO enrichment analysis recently revealed serotonin pathway 
genes, particularly those involved in serotonin re- uptake, to be 
the most differentially expressed genes between IBS patients and 
healthy controls.44 Furthermore, interaction of eight of these pre-
dicted transcription factors was proven based on ChIP Atlas data.
Regulation of expression by alternative promoters and various 
splicing isoforms leads to profound molecular heterogeneity. Within 
GenBank, seven human SLC6A4 isoforms driven by the P1 and P2 
promoters are currently annotated (AK313166 and AK308014 by P1 
and L05568, AK309538, AY902473, BC069484 and X70697 by P2) 
underlining the molecular heterogeneity of SLC6A4. Furthermore, 
gene expression is regulated by micro- RNAs (miRNAs) in IBS.11 
Of note, the miR- 16 family that we recently found to be down-
regulated in IBS45,46 was reported to modulate SERT expression 
within the brain47 and presumably also regulates SERT expression 
in the GI tract. Furthermore, miR- 24 was found to be upregulated, 
whereas SERT was downregulated in the intestinal mucosa of IBS- D 
patients.48 In an animal model of IBS, miR- 24 was found to trigger 
symptoms including visceral pain.48 SLC6A4 regulation was recently 
summarized in a comprehensive review.49 Regulation of SLC6A4 
expression is complex, and it is currently unknown how the differ-
ent isoforms are expressed and how miRNAs and/or polymorphic 
sites modulate the various functions of the serotonergic system. 
Bidirectional communication between the gut and the brain via the 
brain- gut/gut- brain axis might be modified by cis- regulatory poly-
morphisms that drive gene expression and control gene function in 
specific subregions/organs differently.
Our study has some limitations. We combined data from 13 cen-
tres from different countries, so methodological discrepancies exist. 
Only one SNP was genotyped, so we could not correct our results 
for population stratification using genetic principal components. To 
mitigate potential bias, we only included individuals of European an-
cestry. Since all participants were Caucasians, our association find-
ing may not equally apply to the other populations. Also, the SNP 
genotype frequencies significantly deviated from the HWE expecta-
tion in patients from the Greek cohort, which we cannot explain at 
present. However, the estimated effect size and direction are in line 
with the overall results.
Another limitation is that we did not define the IBS phenotype 
according to a uniform symptom classification— we used Rome II and/
or Rome III criteria. The Rome III criteria50 allow a wider variation in 
diagnostic identification of IBS, particularly of the IBS subtypes. We 
also analysed more females than males because the prevalence of 
IBS is higher in women. Accordingly, we cannot conclude that the 
identified SNP would not be associated with IBS- C in males in a co-
hort containing more male patients.
GI phenotypes were not examined in control individuals, so 
we cannot exclude that IBS patients were in the control sample. 
Moreover, because of symptom- based classifications and heteroge-
neity, we cannot exclude that enrolled patients had the same diseases 
and aetiopathogenetic mechanisms. For genetic studies, a purely 
symptom- based IBS classification (based solely on bowel function) is 
not specific enough to identify mechanistically diverse phenotypes 
of IBS or its subgroups.11 Therefore, additional parameters, as well 
as intermediate phenotypes or quantitative traits, are mandatory 
to dissect genetic patterns underlying IBS and to correlate these to 
symptoms/markers. As recently established by GENIEUR,46 deep 
phenotypic characterization of patients is mandatory and should 
be based on the following criteria: clinical examination and specific 
questionnaires (assessing not only GI but also psychiatric comorbid-
ity, personality traits and somatization), assessment of laboratory 
parameters and tissue sampling to follow- up changes in expression 
in certain candidates. Control individuals should be characterized in 
a similar way to avoid including IBS patients in the control sample. 
However, most of the samples analysed in this study were collected 
before the GENIEUR phenotyping tool was established, so do not 
follow that standard.51 Some studies showed that the IBS subtype 
may change over time, which is another limitation. For example, one 
study found that IBS- C changed to IBS- D or vice versa in 14% of fe-
male patients.52 In addition, many of our samples came from tertiary 
referral centres, so may not be generalizable to all IBS patients.
Another limitation is the small number of samples in the differen-
tial expression analysis. However, a strength of our study is that we 
analysed expression in the small and large intestine, unlike previous 
studies that focussed on only one or two gut regions.53
In conclusion, we confirmed that the novel promoter P2 is the 
predominant driver of SERT expression in the gut and that a func-
tionally relevant SNP in SLC6A4 is associated with IBS- C in females. 
This underlines the relevance of SERT in IBS pathogenesis. To what 
extent this SNP shapes the GI phenotype in IBS and how it interferes 
with other brain- related genetic variants and impacts bidirectional 
communication between the gut and the brain remain unanswered. 
Our future studies within the international H2020 consortium 
DISCOvERIE (Development, dIagnosis and prevention of gender- related 
Somatic and mental COmorbiditiEs in iRritable Bowel Syndrome In 
Europe, www.DISCO vERIE.eu) that implemented GENIEUR guide-
lines will allow us to investigate how these variants correlate with 
behaviour, pain perception and bowel habits and how far gene- gene 
and gene- environment interactions affect individual susceptibility 
to chronic GI disorders. A better understanding of potential SERT 
regulators is of clinical importance and may provide insight into IBS 
pathophysiology and SERT- directed therapeutic interventions.
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